165 related articles for article (PubMed ID: 28639280)
1. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract][Full Text] [Related]
2. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
3. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
4. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
Wang L; Allison D; Shukla PS
Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
[TBL] [Abstract][Full Text] [Related]
5. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
6. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
[TBL] [Abstract][Full Text] [Related]
7. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
Ali RH; Seidman JD; Luk M; Kalloger S; Gilks CB
Int J Gynecol Pathol; 2012 Nov; 31(6):499-506. PubMed ID: 23018212
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic features observation of ovarian transitional cell tumors].
Wang L; Dong Y; Li Q; Li H; Sun X; Zhou X; Li X
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):118-22. PubMed ID: 25916643
[TBL] [Abstract][Full Text] [Related]
9. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract][Full Text] [Related]
10. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins.
Riedel I; Czernobilsky B; Lifschitz-Mercer B; Roth LM; Wu XR; Sun TT; Moll R
Virchows Arch; 2001 Feb; 438(2):181-91. PubMed ID: 11253121
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
12. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
[TBL] [Abstract][Full Text] [Related]
13. Brenner tumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder.
Ordóñez NG; Mackay B
Ultrastruct Pathol; 2000; 24(3):157-67. PubMed ID: 10914427
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric DNA analysis of ovarian Brenner tumors and transitional cell carcinomas.
Martin AR; Kotylo PK; Kennedy JC; Fineberg NS; Roth LM
Int J Gynecol Pathol; 1992 Jul; 11(3):188-96. PubMed ID: 1399228
[TBL] [Abstract][Full Text] [Related]
15. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
16. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
[TBL] [Abstract][Full Text] [Related]
17. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
18. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
[TBL] [Abstract][Full Text] [Related]
20. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
